Home Newsfeeds Goldman Sachs Maintains Neutral on Centessa Pharmaceuticals, Lowers Price Target to $4

Goldman Sachs Maintains Neutral on Centessa Pharmaceuticals, Lowers Price Target to $4

Goldman Sachs analyst Salveen Richter maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Neutral and lowers the price target from $5 to $4.

byBenzinga Newsdesk

August 11, 2022

1 minute read

Goldman Sachs analyst Salveen Richter maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Neutral and lowers the price target from $5 to $4.

M&A
News

Warren Buffett’s Berkshire Hathaway Boosts Stake in Occidental Petroleum as Oil Industry Sees Shakeups

By Anusuya Lahiri

October 26, 12:16 PM

Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) ramped up stake in Occidental Petroleum Corp (NYSE: OXY) as

CVX

Weber Withdraws 2022 Net Sales, Adj. EBITDA Guidance

By Benzinga Newsdesk

July 25, 8:45 AM

Weber Announces Management Transition and Provides Business Update Alan Matula Appointed Interim CEO Company Provides Preliminary Estimates for Fiscal Third Quarter 2022 Results; Will Report Final

WEBR

Atlas Lithium Expands Lithium Exploration Expertise With Appointment Of Chief Geologist James Abson

By Benzinga Newsdesk

October 2, 9:06 AM

Atlas Lithium Corporation (NASDAQ:ATLX) ("Atlas Lithium" or "Company"), a leading mineral exploration and development company, is pleased to announce that it has hired James Abson as Chief Geology Officer. This

ATLX